Navigation Links
Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model

PITTSBURGH, June 19 /PRNewswire/ -- Cohera Medical Inc. today announced that data published in the July issue of Plastic and Reconstructive Surgery show the company's surgical adhesive, TissuGlu, was effective in preventing the formation of seroma in an animal abdominoplasty model.

Summarized in a paper titled "Lysine-Derived Urethane Surgical Adhesive Prevents Seroma Formation in a Canine Abdominoplasty Model," (Plast. Reconstr. Surg. 2008; Vol. 122, Issue 1: 95-102) the results demonstrated that TissuGlu successfully prevented the formation of seroma in a novel large-animal model designed to evaluate seroma formation. While the control side in all seven animals used in the study demonstrated large, clinically significant seromas, the side treated with TissuGlu showed little or no evidence of fluid accumulation. In addition, histologic analysis of tissue samples from the animals showed no signs of inflammation or foreign body reaction associated with the adhesive.

"I am impressed with the experimental data that demonstrate a clear ability of the adhesive to control seroma formation in this animal model," said J. Peter Rubin, M.D., founder and director of the Life After Weight Loss surgical body contouring program at the University of Pittsburgh and the lead author of the paper. "This adhesive shows strong potential for widespread applications in many surgical specialties."

Surgeons have expressed a strong need for a product that adheres tissue flaps to help prevent the fluid accumulation that occurs between tissue layers after surgery. Surgical adhesives available today fall into two categories: "superglue"-type products that are strong but cannot be used inside the body because they break down into toxic byproducts and "fibrin sealant" products that are biocompatible but create a weak bond and are expensive and difficult to prepare during surgery.

"Seromas have been a major problem for post-surgical patients," said Susan E. Downey, M.D., a board-certified plastic surgeon at the Pacific SurgiCenter in Santa Monica, Calif. "This study demonstrates a great animal model and the efficacious use of an adhesive to address this difficult problem."

"The results illustrate the potential efficacy of TissuGlu and helps support the movement of TissuGlu into human clinical studies, which we expect to initiate next year," said Patrick Daly, president and CEO of Cohera Medical. "Our goal is to introduce to surgeons a tissue adhesive that encompasses the desired strong and effective bonding properties in a safe, resorbable and easy-to-use formulation."

Seroma formation is a frequent complication of plastic surgery procedures such as abdominoplasty, with complication rates ranging from 15 percent to 52 percent. In 2007, approximately 148,000 abdominoplasty, or "tummy tuck," procedures were performed in the United States, according to the American Society of Plastic Surgeons.

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the US or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.

SOURCE Cohera Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Long-term safety data on Lialda published in leading GI journal
2. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
3. New Regulations for Hospice Provision Published by CMS
4. First Comprehensive Reference on Evidence-Based Design Published
5. Premier issue of Environmental Justice just published
6. Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
7. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
8. Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
9. 20th Edition of the Encyclopedia of Social Work Published
10. Clinical guidelines for the manual titration of PAP in OSA patients published in JCSM
11. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: